About Generation Bio Co. (GBIO) — Dividend Analysis 2026
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Is GBIO a good dividend investment in 2026?
GBIO offers a 37.45% forward yield with a 50% payout ratio. Strand Safety Score: 15/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
GBIO DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your GBIO portfolio grows to $240.7K vs $47.5K without reinvestment. This is the compound interest effect in action.
GBIO dividend growth history & forecast
GBIO has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 37.45%.
Company generates negative FCF ($-91M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.1B → -0.1B → -0.1B
15 / 30 pts
15/30
Net income grew in the latest year — positive but trend is unconfirmed
OVERALL ASSESSMENT
High risk of dividend cut — weak fundamentals across multiple factors.
STRAND SCORE
15
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 GBIO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold GBIO.
Gross yield
37.45%
Tax rate
15.00%
After-tax yield
31.83%
Real yield (−CPI)
29.03%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
37.45%
34.65%
$3,745 / yr
🇺🇸 US Taxable (15%) ✓
15%
31.83%
29.03%
$3,183 / yr
🇺🇸 US Taxable (20%)
20%
29.96%
27.16%
$2,996 / yr
🇬🇧 UK ISA
0%
37.45%
34.65%
$3,745 / yr
🇬🇧 UK Taxable
8.75%
34.17%
31.37%
$3,417 / yr
🇨🇦 TFSA
0%
37.45%
34.65%
$3,745 / yr
🇨🇦 CA Taxable
25%
28.09%
25.29%
$2,809 / yr
🇦🇺 Super (pension)
15%
31.83%
29.03%
$3,183 / yr
🇦🇺 AU Taxable
30%
26.21%
23.41%
$2,622 / yr
🇩🇪 DE Taxable
26.375%
27.57%
24.77%
$2,757 / yr
🇫🇷 FR Taxable
30%
26.21%
23.41%
$2,622 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 GBIO Income Goal & Break-Even
Dividend Break-Even
4yr
Years for dividends to fully repay your GBIO investment of $5.34/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$148.6K
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$146.1K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in GBIO for:
Shares needed
14,118
Capital required
$75,390
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 GBIO Dividend Payment Schedule
GBIO pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 GBIO vs Healthcare Benchmarks
How GBIO compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+34.65% vs sectorBetter
GBIO
37.45%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
GBIO
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
GBIO
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GBIO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ GBIO Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
Atlas Venture Fund X, L.P.
10 percent owner
U-Tender
2026-02-09
60
$0.00
—
Stehman-Breen Catherine
director
D-Return
2026-02-09
6,000
$33.20
$199.2K
Stehman-Breen Catherine
director
D-Return
2026-02-09
3,000
$3.87
$11.6K
Stehman-Breen Catherine
director
D-Return
2026-02-09
5,200
$190.00
$988.0K
Stehman-Breen Catherine
director
D-Return
2026-02-09
1,500
$265.90
$398.9K
Stehman-Breen Catherine
director
D-Return
2026-02-09
1,920
$61.90
$118.8K
Stehman-Breen Catherine
director
D-Return
2026-02-09
2,500
$48.30
$120.8K
Stehman-Breen Catherine
director
U-Tender
2026-02-09
4,752
$0.00
—
Rowland Charles A Jr
director
D-Return
2026-02-09
1,920
$61.90
$118.8K
Rowland Charles A Jr
director
D-Return
2026-02-09
6,000
$33.20
$199.2K
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
🎯
Analyst Price Target
Wall Street consensus
Current Price
$5.34
Analyst Target
$5.25
Upside / Downside
-1.7%
Range
$5.00 – $5.50
💡 If GBIO reaches the analyst target of $5.25, investors buying today at $5.34 would see an effective yield of 38.10% on shares purchased at target price — vs 37.45% at current price.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
🔬
Financial Health Scores
Altman Z-Score
-9.12
🔴 Distress Zone — elevated dividend cut risk
Safe: >3.0 · Grey: 1.81–3.0 · Distress: <1.81
Piotroski F-Score
1/9
🔴 Weak fundamentals — dividend safety concern
Strong: 7–9 · Moderate: 4–6 · Weak: 0–3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
🟡
Net Insider Sentiment: Neutral0 buys · 0 sells · last 90 days
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GBIO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →